uniQure Faces Class Action Lawsuit Amid Stock Plunge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy QURE?
Source: Globenewswire
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against uniQure N.V., alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiffs by April 13, 2026, indicating significant legal risks that could undermine company reputation and shareholder confidence.
- FDA Feedback Impact: In a press release dated November 3, 2025, uniQure revealed that the FDA's feedback on its AMT-130 gene therapy suggests that previous clinical data may not suffice for a Biologics License Application (BLA), marking a critical shift in communications with the FDA that could delay product approval.
- Stock Price Plunge: Following the negative FDA feedback, uniQure's stock price plummeted by $33.40, or 49.34%, closing at $34.29 on November 3, 2025, reflecting market pessimism regarding the company's future prospects.
- Legal Affairs Impact: Pomerantz LLP, recognized for its expertise in securities litigation, underscores its commitment to fighting securities fraud, suggesting that this lawsuit could have profound implications for uniQure's financial health and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 23.430
Low
33.00
Averages
49.88
High
70.00
Current: 23.430
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against uniQure N.V., seeking damages for investors who purchased securities between September 24 and October 31, 2025, reflecting strong investor response to potential violations by the company.
- Detailed Allegations: The complaint alleges that uniQure's executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approvals, which could mislead investors about the company's prospects and undermine market confidence.
- BLA Submission Delay Risk: The lawsuit highlights that despite purportedly successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, negatively impacting the company's future revenue and market performance.
- Investor Recourse Opportunity: Investors have until April 13, 2026, to apply to be lead plaintiffs, indicating the legal pressure the company faces, which may compel it to take actions to restore investor trust.
See More
Notice to Shareholders of uniQure N.V. Regarding Class Action Lawsuit
- Lawsuit Notification Issued: The Gross Law Firm has issued a notice to shareholders who purchased shares of uniQure N.V. (NASDAQ:QURE) between September 24, 2025, and October 31, 2025, encouraging them to contact the firm for potential lead plaintiff appointment, indicating significant legal risks that could affect shareholder interests.
- Overview of Allegations: The lawsuit alleges that uniQure failed to fully secure FDA approval for the design of its pivotal study and downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline, which could mislead investors regarding the company's prospects and operational integrity.
- Critical Deadline: Shareholders must register by April 13, 2026, to participate in the class action, and failure to do so may result in the loss of their right to claim, highlighting the urgency of the legal process and its potential impact on investors.
- Participation Instructions: Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate, demonstrating the firm's commitment to protecting investor rights.
See More
Class Action Notice for uniQure N.V. Investors
- Class Action Notice: The Portnoy Law Firm advises investors of uniQure N.V. regarding a class action for those who purchased securities between September 24 and October 31, 2025, with a deadline of April 13, 2026, for filing a lead plaintiff motion to protect their legal rights.
- FDA Feedback Impact: On November 3, 2025, uniQure announced that the FDA indicated during a Biologics License Application meeting that data from AMT-130's clinical trials may not be sufficient for BLA submission, marking a significant shift in the company's regulatory outlook and creating uncertainty around the submission timeline.
- Stock Price Plunge: Following the FDA feedback, uniQure's stock price fell by $33.40, or 49.34%, closing at $34.29 per share on November 3, 2025, reflecting market concerns regarding the company's future prospects and investor confidence.
- Legal Support Services: The Portnoy Law Firm offers complimentary case evaluations to assist investors in pursuing claims for losses incurred due to corporate wrongdoing, highlighting the firm's commitment to protecting investor rights and providing necessary legal support.
See More
uniQure Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruq & Faruq LLP is investigating potential claims against uniQure N.V., particularly for investors who purchased securities between September 24 and October 31, 2025, urging them to seek lead plaintiff status by the April 13, 2026 deadline.
- FDA Approval Issues: The complaint alleges that uniQure and its executives violated federal securities laws by failing to disclose that the design of their pivotal study was not fully approved by the FDA, leading to investor misconceptions about the company's prospects and impacting decision-making.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA no longer agreed that the data would support a BLA submission, uniQure's stock price plummeted by 49%, from $67.69 to $34.29, reflecting strong market concerns about the company's future.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with information regarding uniQure's conduct, including whistleblowers and former employees, to contact them to ensure investor rights are protected.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that they must file lead plaintiff applications by April 13, 2026, for shares purchased between September 24 and October 31, 2025, highlighting the growing concern over the company's legal risks among investors.
- Disclosure Failures: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA accelerated approval for their drug candidate AMT-130.
- Stock Price Plunge: Following the November 3, 2025 disclosure regarding FDA's stance on AMT-130, the stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, indicating extreme market pessimism about the company's future prospects.
- Legal Implications: The case is pending in the Southern District of New York, and investors need to monitor the lawsuit's progress to take timely action to protect their interests, reflecting a strong demand for corporate governance and transparency.
See More
Notice of Class Action Lawsuit for uniQure N.V. Shareholders
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of uniQure N.V. (NASDAQ: QURE), encouraging those who purchased shares during the class period from September 24, 2025, to October 31, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery.
- Allegations Details: The complaint alleges that uniQure failed to fully secure FDA approval for the design of its pivotal study and downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to additional studies, resulting in misleading statements about the company's business prospects.
- Registration Deadline: Shareholders must register by April 13, 2026, to participate in the class action, and upon registration, they will receive updates throughout the case lifecycle, ensuring they remain informed about the proceedings.
- Law Firm Background: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to false statements or omissions by companies, emphasizing the need for responsible business practices.
See More
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against uniQure N.V., seeking damages for investors who purchased securities between September 24 and October 31, 2025, reflecting strong investor response to potential violations by the company.
- Detailed Allegations: The complaint alleges that uniQure's executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approvals, which could mislead investors about the company's prospects and undermine market confidence.
- BLA Submission Delay Risk: The lawsuit highlights that despite purportedly successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, negatively impacting the company's future revenue and market performance.
- Investor Recourse Opportunity: Investors have until April 13, 2026, to apply to be lead plaintiffs, indicating the legal pressure the company faces, which may compel it to take actions to restore investor trust.
See More
Notice to Shareholders of uniQure N.V. Regarding Class Action Lawsuit
- Lawsuit Notification Issued: The Gross Law Firm has issued a notice to shareholders who purchased shares of uniQure N.V. (NASDAQ:QURE) between September 24, 2025, and October 31, 2025, encouraging them to contact the firm for potential lead plaintiff appointment, indicating significant legal risks that could affect shareholder interests.
- Overview of Allegations: The lawsuit alleges that uniQure failed to fully secure FDA approval for the design of its pivotal study and downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline, which could mislead investors regarding the company's prospects and operational integrity.
- Critical Deadline: Shareholders must register by April 13, 2026, to participate in the class action, and failure to do so may result in the loss of their right to claim, highlighting the urgency of the legal process and its potential impact on investors.
- Participation Instructions: Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate, demonstrating the firm's commitment to protecting investor rights.
See More
Class Action Notice for uniQure N.V. Investors
- Class Action Notice: The Portnoy Law Firm advises investors of uniQure N.V. regarding a class action for those who purchased securities between September 24 and October 31, 2025, with a deadline of April 13, 2026, for filing a lead plaintiff motion to protect their legal rights.
- FDA Feedback Impact: On November 3, 2025, uniQure announced that the FDA indicated during a Biologics License Application meeting that data from AMT-130's clinical trials may not be sufficient for BLA submission, marking a significant shift in the company's regulatory outlook and creating uncertainty around the submission timeline.
- Stock Price Plunge: Following the FDA feedback, uniQure's stock price fell by $33.40, or 49.34%, closing at $34.29 per share on November 3, 2025, reflecting market concerns regarding the company's future prospects and investor confidence.
- Legal Support Services: The Portnoy Law Firm offers complimentary case evaluations to assist investors in pursuing claims for losses incurred due to corporate wrongdoing, highlighting the firm's commitment to protecting investor rights and providing necessary legal support.
See More
uniQure Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruq & Faruq LLP is investigating potential claims against uniQure N.V., particularly for investors who purchased securities between September 24 and October 31, 2025, urging them to seek lead plaintiff status by the April 13, 2026 deadline.
- FDA Approval Issues: The complaint alleges that uniQure and its executives violated federal securities laws by failing to disclose that the design of their pivotal study was not fully approved by the FDA, leading to investor misconceptions about the company's prospects and impacting decision-making.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA no longer agreed that the data would support a BLA submission, uniQure's stock price plummeted by 49%, from $67.69 to $34.29, reflecting strong market concerns about the company's future.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with information regarding uniQure's conduct, including whistleblowers and former employees, to contact them to ensure investor rights are protected.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that they must file lead plaintiff applications by April 13, 2026, for shares purchased between September 24 and October 31, 2025, highlighting the growing concern over the company's legal risks among investors.
- Disclosure Failures: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA accelerated approval for their drug candidate AMT-130.
- Stock Price Plunge: Following the November 3, 2025 disclosure regarding FDA's stance on AMT-130, the stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, indicating extreme market pessimism about the company's future prospects.
- Legal Implications: The case is pending in the Southern District of New York, and investors need to monitor the lawsuit's progress to take timely action to protect their interests, reflecting a strong demand for corporate governance and transparency.
See More
Notice of Class Action Lawsuit for uniQure N.V. Shareholders
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of uniQure N.V. (NASDAQ: QURE), encouraging those who purchased shares during the class period from September 24, 2025, to October 31, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery.
- Allegations Details: The complaint alleges that uniQure failed to fully secure FDA approval for the design of its pivotal study and downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to additional studies, resulting in misleading statements about the company's business prospects.
- Registration Deadline: Shareholders must register by April 13, 2026, to participate in the class action, and upon registration, they will receive updates throughout the case lifecycle, ensuring they remain informed about the proceedings.
- Law Firm Background: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to false statements or omissions by companies, emphasizing the need for responsible business practices.
See More
